|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 366 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Rheumatoid Arthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Rheumatoid Arthritis
- Rheumatoid Arthritis Therapeutics under Development by Companies
- Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Rheumatoid Arthritis Therapeutics – Products under Development by Companies
- Rheumatoid Arthritis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Rheumatoid Arthritis Therapeutics Development
- Alcon, Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Biogen Idec Inc.
- Amgen Inc.
- Antares Pharma, Inc.
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Genentech, Inc.
- Inovio Biomedical Corporation
- MedImmune LLC
- Isis Pharmaceuticals, Inc.
- Biotest AG
- Merck & Co., Inc.
- Santen Pharmaceutical Co., Ltd.
- Ablynx
- AbGenomics International, Inc.
- Novo Nordisk A/S
- Albany Molecular Research, Inc.
- Plexxikon Inc.
- BioLineRx, Ltd.
- arGentis Pharmaceuticals, LLC
- Reliance Life Sciences Pvt. Ltd.
- MediGene AG
- Celltrion, Inc.
- Nycomed International Management GmbH
- TiGenix NV
- Pacira Pharmaceuticals, Inc.
- Novartis AG
- Astellas Pharma Inc.
- Biocon Limited
- Cephalon, Inc.
- Chugai Pharmaceutical Co. Ltd
- Cipla Ltd.
- Daewoong Pharmaceutical Co., Ltd.
- Gedeon Richter Plc.
- Glenmark Pharmaceuticals Ltd.
- Kissei Pharmaceutical Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- MDRNA, Inc.
- Pfizer Inc.
- Rigel Pharmaceuticals, Inc.
- Santarus, Inc.
- Teva Pharmaceutical Industries Limited
- Toyama Chemical Co. Ltd
- UCB Group
- Vertex Pharmaceuticals Incorporated
- Zydus Cadila Healthcare Limited
- Genmab A/S
- novosom AG
- Paratek Pharmaceuticals, Inc.
- CEL-SCI Corporation
- Celgene Corporation
- Onyx Pharmaceuticals, Inc.
- Merck KGaA
- Bone Medical Limited
- Access Pharmaceuticals, Inc.
- 4SC AG
- 3SBio Inc.
- Addex Pharmaceuticals
- EntreMed, Inc.
- Evotec Aktiengesellschaft
- Genesis Research and Development Corporation Ltd.
- Hollis-Eden Pharmaceuticals, Inc.
- IMMUNOMEDICS, INC
- Can-Fite BioPharma Ltd.
- Idera Pharmaceuticals, Inc.
- Karo Bio
- Ligand Pharmaceuticals Incorporated
- Almirall, S.A.
- Lupin Limited
- Medivir AB
- Bionomics Limited
- PROLOR Biotech, Inc.
- Nutra Pharma Corporation
- Compugen Ltd.
- Lexicon Pharmaceuticals, Inc.
- Arena Pharmaceuticals, Inc.
- Alexion Pharmaceuticals, Inc.
- Portola Pharmaceuticals, Inc.
- Chelsea Therapeutics, Inc.
- CombinatoRx, Incorporated
- Yuhan Corporation
- KOLON LIFE SCIENCE INC.
- Zenotech Laboratories Limited
- Regeneron Pharmaceuticals, Inc.
- Pharmacyclics, Inc.
- Protalix BioTherapeutics, Inc.
- Cytomedix, Inc.
- Tolerx, Inc.
- Antisoma plc
- MorphoSys AG
- Boryung Pharmaceutical Co., Ltd.
- Green Cross Corporation
- Hanall Pharmaceutical Co., Ltd.
- LG Life Sciences, Ltd
- AnGes MG, Inc.
- Biotie Therapies Corp.
- Transition Therapeutics Inc.
- Galapagos NV
- Panacea Biotec Limited
- Sareum Holdings plc
- Protalex, Inc.
- Proximagen Neuroscience plc.
- Newron Pharmaceuticals S.p.A.
- DiaMedica Inc.
- Morphotek, Inc.
- Spectrum Pharmaceuticals, Inc.
- Advinus Therapeutics Pvt. Ltd.
- Auspex Pharmaceuticals
- Affimed Therapeutics AG
- Ambit Biosciences Corporation
- AnaMar Medical AB
- Viron Therapeutics, Inc.
- Immupharma Plc
- Palau Pharma S.A
- Philogen S.p.A.
- Probiodrug AG
- Acceleron Pharma, Inc.
- Phenex Pharmaceuticals AG
- Neovacs SA
- MIKA Pharma GmbH
- Hutchison MediPharma Limited
- CREABILIS Therapeutics S.r.l.
- Artielle ImmunoTherapeutics, Inc.
- BioNumerik Pharmaceuticals, Inc.
- InCode BioPharmaceutics, Inc.
- Aegera Therapeutics Inc.
- Amura Holdings Ltd.
- JADO Technologies GmbH.
- Alder Biopharmaceuticals Inc.
- IMMD Inc.
- Circassia Holdings Ltd.
- Funxional Therapeutics Ltd
- Catabasis Pharmaceuticals, Inc.
- Antyra, Inc.
- Recoly N.V.
- Opsona Therapeutics Ltd.
- Asahi Kasei Pharma
- Vaccinex, Inc.
- Syntrix Biosystems, Inc.
- S*BIO Pte Ltd
- Deciphera Pharmaceuticals, LLC
- MSM Protein Technologies, Inc.
- Vascular Biogenics Ltd.
- Indus Biotech Private Limited
- Txcell SA
- Endocyte, Inc.
- Theraclone Sciences, Inc.
- Theracos, Inc.
- TcL Pharma SAS
- Versartis, Inc.
- Cardax Pharmaceuticals, Inc.
- Myriad Pharmaceuticals, Inc.
- Inimex Pharmaceuticals, Inc.
- Omeros Corporation
- Xencor, Inc.
- Acetylon Pharmaceuticals, Inc.
- Trillium Therapeutics Inc.
- BaroFold, Inc.
- CBio Limited
- VentiRx Pharmaceuticals, Inc.
- KaloBios Pharmaceuticals, Inc.
- AB Science
- Provid Pharmaceuticals, Inc.
- Biokine Therapeutics Ltd.
- OncoImmune, Inc.
- Medistem, Inc.
- Avesthagen Limited
- KAHR medical Ltd.
- SuppreMol GmbH
- Viromed Co., Ltd.
- Ferring Pharmaceuticals, Inc.
- Aphoenix, Inc.
- Taisho Toyama Pharmaceutical Co., Ltd
- Domainex Ltd.
- Cellceutix Pharmaceuticals, Inc.
- Dynamix Pharmaceuticals Ltd.
- Amplimmune, Inc.
- Lycera Corp.
- Perseid Therapeutics LLC
- OHR Pharmaceutical Inc.
- ImmunoFrontier, Inc.
- Femta Pharmaceuticals, Inc.
- Cellmid Ltd
- Mebiopharm Co., Ltd.
- ToleroTech Inc.
- Diurnal Ltd
- Rheumatoid Arthritis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- REGN88 - Drug Profile
- LY2127399 - Drug Profile
- Tofacitinib - Drug Profile
- AIN457 - Drug Profile
- Actemra - Drug Profile
- Actemra - Drug Profile
- Cimzia - Drug Profile
- Cimzia - Drug Profile
- Arcoxia - Drug Profile
- Duexis - Drug Profile
- AB1010 - Drug Profile
- Arzerra - Drug Profile
- Fostamatinib - Drug Profile
- Methotrexate + Triamcinolone Hexacetonide + Adalimumab - Drug Profile
- Simponi - Drug Profile
- Simponi - Drug Profile
- Remsima - Drug Profile
- PG-201 - Drug Profile
- T-614 + Methotrexate - Drug Profile
- Etanercept Biosimilar - Drug Profile
- HD203 - Drug Profile
- Biosimilar Etanercept - Drug Profile
- RAVAX - Drug Profile
- Infliximab Biosimilar + Methotrexate - Drug Profile
- Rheumatoid Arthritis Therapeutics – Drug Profile Updates
- Rheumatoid Arthritis Therapeutics – Discontinued Products
- Rheumatoid Arthritis Therapeutics - Dormant Products
- Rheumatoid Arthritis – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Rheumatoid Arthritis, H2 2012
- Products under Development for Rheumatoid Arthritis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Development by Companies, H2 2012 (Contd..5)
- Number of Products under Development by Companies, H2 2012 (Contd..6)
- Number of Products under Development by Companies, H2 2012 (Contd..7)
- Number of Products under Development by Companies, H2 2012 (Contd..8)
- Number of Products under Development by Companies, H2 2012 (Contd..9)
- Number of Products under Development by Companies, H2 2012 (Contd..10)
- Number of Products under Development by Companies, H2 2012 (Contd..11)
- Number of Products under Development by Companies, H2 2012 (Contd..12)
- Number of Products under Development by Companies, H2 2012 (Contd..13)
- Number of Products under Development by Companies, H2 2012 (Contd..14)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Development by Companies, H2 2012 (Contd..6)
- Products under Development by Companies, H2 2012 (Contd..7)
- Products under Development by Companies, H2 2012 (Contd..8)
- Products under Development by Companies, H2 2012 (Contd..9)
- Products under Development by Companies, H2 2012 (Contd..10)
- Products under Development by Companies, H2 2012 (Contd..11)
- Products under Development by Companies, H2 2012 (Contd..12)
- Products under Development by Companies, H2 2012 (Contd..13)
- Products under Development by Companies, H2 2012 (Contd..14)
- Products under Development by Companies, H2 2012 (Contd..15)
- Products under Development by Companies, H2 2012 (Contd..16)
- Products under Development by Companies, H2 2012 (Contd..17)
- Products under Development by Companies, H2 2012 (Contd..18)
- Products under Development by Companies, H2 2012 (Contd..19)
- Products under Investigation by Universities/Institutes, H2 2012
- Alcon, Inc., H2 2012
- Bristol-Myers Squibb Company, H2 2012
- Johnson & Johnson, H2 2012
- F. Hoffmann-La Roche Ltd., H2 2012
- Abbott Laboratories, H2 2012
- Biogen Idec Inc., H2 2012
- Amgen Inc., H2 2012
- Antares Pharma, Inc., H2 2012
- AstraZeneca PLC, H2 2012
- Eli Lilly and Company, H2 2012
- GlaxoSmithKline plc, H2 2012
- Genentech, Inc., H2 2012
- Inovio Biomedical Corporation, H2 2012
- MedImmune LLC, H2 2012
- Isis Pharmaceuticals, Inc., H2 2012
- Biotest AG, H2 2012
- Merck & Co., Inc., H2 2012
- Santen Pharmaceutical Co., Ltd., H2 2012
- Ablynx, H2 2012
- AbGenomics International, Inc., H2 2012
- Novo Nordisk A/S, H2 2012
- Albany Molecular Research, Inc., H2 2012
- Plexxikon Inc., H2 2012
- BioLineRx, Ltd., H2 2012
- arGentis Pharmaceuticals, LLC, H2 2012
- Reliance Life Sciences Pvt. Ltd., H2 2012
- MediGene AG, H2 2012
- Celltrion, Inc., H2 2012
- Nycomed International Management GmbH, H2 2012
- TiGenix NV, H2 2012
- Pacira Pharmaceuticals, Inc., H2 2012
- Novartis AG, H2 2012
- Astellas Pharma Inc., H2 2012
- Biocon Limited, H2 2012
- Cephalon, Inc., H2 2012
- Chugai Pharmaceutical Co. Ltd, H2 2012
- Cipla Ltd., H2 2012
- Daewoong Pharmaceutical Co., Ltd., H2 2012
- Gedeon Richter Plc., H2 2012
- Glenmark Pharmaceuticals Ltd., H2 2012
- Kissei Pharmaceutical Co., Ltd., H2 2012
- Mitsubishi Tanabe Pharma Corporation, H2 2012
- MDRNA, Inc., H2 2012
- Pfizer Inc., H2 2012
- Rigel Pharmaceuticals, Inc., H2 2012
- Santarus, Inc., H2 2012
- Teva Pharmaceutical Industries Limited, H2 2012
- Toyama Chemical Co. Ltd, H2 2012
- UCB Group, H2 2012
- Vertex Pharmaceuticals Incorporated, H2 2012
- Zydus Cadila Healthcare Limited, H2 2012
- Genmab A/S, H2 2012
- novosom AG, H2 2012
- Paratek Pharmaceuticals, Inc., H2 2012
- CEL-SCI Corporation, H2 2012
- Celgene Corporation, H2 2012
- Onyx Pharmaceuticals, Inc., H2 2012
- Merck KGaA, H2 2012
- Bone Medical Limited, H2 2012
- Access Pharmaceuticals, Inc., H2 2012
- 4SC AG, H2 2012
- 3SBio Inc., H2 2012
- Addex Pharmaceuticals, H2 2012
- EntreMed, Inc., H2 2012
- Evotec Aktiengesellschaft, H2 2012
- Genesis Research and Development Corporation Ltd., H2 2012
- Hollis-Eden Pharmaceuticals, Inc., H2 2012
- IMMUNOMEDICS, INC, H2 2012
- Can-Fite BioPharma Ltd., H2 2012
- Idera Pharmaceuticals, Inc., H2 2012
- Karo Bio, H2 2012
- Ligand Pharmaceuticals Incorporated, H2 2012
- Almirall, S.A., H2 2012
- Lupin Limited, H2 2012
- Medivir AB, H2 2012
- Bionomics Limited, H2 2012
- PROLOR Biotech, Inc., H2 2012
- Nutra Pharma Corporation, H2 2012
- Compugen Ltd., H2 2012
- Lexicon Pharmaceuticals, Inc., H2 2012
- Arena Pharmaceuticals, Inc., H2 2012
- Alexion Pharmaceuticals, Inc., H2 2012
- Portola Pharmaceuticals, Inc., H2 2012
- Chelsea Therapeutics, Inc., H2 2012
- CombinatoRx, Incorporated, H2 2012
- Yuhan Corporation, H2 2012
- KOLON LIFE SCIENCE INC., H2 2012
- Zenotech Laboratories Limited, H2 2012
- Regeneron Pharmaceuticals, Inc., H2 2012
- Pharmacyclics, Inc., H2 2012
- Protalix BioTherapeutics, Inc., H2 2012
- Cytomedix, Inc., H2 2012
- Tolerx, Inc., H2 2012
- Antisoma plc, H2 2012
- MorphoSys AG, H2 2012
- Boryung Pharmaceutical Co., Ltd., H2 2012
- Green Cross Corporation, H2 2012
- Hanall Pharmaceutical Co., Ltd., H2 2012
- LG Life Sciences, Ltd, H2 2012
- AnGes MG, Inc., H2 2012
- Biotie Therapies Corp., H2 2012
- Transition Therapeutics Inc., H2 2012
- Galapagos NV, H2 2012
- Panacea Biotec Limited, H2 2012
- Sareum Holdings plc, H2 2012
- Protalex, Inc., H2 2012
- Proximagen Neuroscience plc., H2 2012
- Newron Pharmaceuticals S.p.A., H2 2012
- DiaMedica Inc., H2 2012
- Morphotek, Inc., H2 2012
- Spectrum Pharmaceuticals, Inc., H2 2012
- Advinus Therapeutics Pvt. Ltd., H2 2012
- Auspex Pharmaceuticals, H2 2012
- Affimed Therapeutics AG, H2 2012
- Ambit Biosciences Corporation, H2 2012
- AnaMar Medical AB, H2 2012
- Viron Therapeutics, Inc., H2 2012
- Immupharma Plc, H2 2012
- Palau Pharma S.A, H2 2012
- Philogen S.p.A., H2 2012
- Probiodrug AG, H2 2012
- Acceleron Pharma, Inc., H2 2012
- Phenex Pharmaceuticals AG, H2 2012
- Neovacs SA, H2 2012
- MIKA Pharma GmbH, H2 2012
- Hutchison MediPharma Limited, H2 2012
- CREABILIS Therapeutics S.r.l., H2 2012
- Artielle ImmunoTherapeutics, Inc., H2 2012
- BioNumerik Pharmaceuticals, Inc., H2 2012
- InCode BioPharmaceutics, Inc., H2 2012
- Aegera Therapeutics Inc., H2 2012
- Amura Holdings Ltd., H2 2012
- JADO Technologies GmbH., H2 2012
- Alder Biopharmaceuticals Inc., H2 2012
- IMMD Inc., H2 2012
- Circassia Holdings Ltd., H2 2012
- Funxional Therapeutics Ltd, H2 2012
- Catabasis Pharmaceuticals, Inc., H2 2012
- Antyra, Inc., H2 2012
- Recoly N.V., H2 2012
- Opsona Therapeutics Ltd., H2 2012
- Asahi Kasei Pharma, H2 2012
- Vaccinex, Inc., H2 2012
- Syntrix Biosystems, Inc., H2 2012
- S*BIO Pte Ltd, H2 2012
- Deciphera Pharmaceuticals, LLC, H2 2012
- MSM Protein Technologies, Inc., H2 2012
- Vascular Biogenics Ltd., H2 2012
- Indus Biotech Private Limited, H2 2012
- Txcell SA, H2 2012
- Endocyte, Inc., H2 2012
- Theraclone Sciences, Inc., H2 2012
- Theracos, Inc., H2 2012
- TcL Pharma SAS, H2 2012
- Versartis, Inc., H2 2012
- Cardax Pharmaceuticals, Inc., H2 2012
- Myriad Pharmaceuticals, Inc., H2 2012
- Inimex Pharmaceuticals, Inc., H2 2012
- Omeros Corporation, H2 2012
- Xencor, Inc., H2 2012
- Acetylon Pharmaceuticals, Inc., H2 2012
- Trillium Therapeutics Inc., H2 2012
- BaroFold, Inc., H2 2012
- CBio Limited, H2 2012
- VentiRx Pharmaceuticals, Inc., H2 2012
- KaloBios Pharmaceuticals, Inc., H2 2012
- AB Science, H2 2012
- Provid Pharmaceuticals, Inc., H2 2012
- Biokine Therapeutics Ltd., H2 2012
- OncoImmune, Inc., H2 2012
- Medistem, Inc., H2 2012
- Avesthagen Limited, H2 2012
- KAHR medical Ltd., H2 2012
- SuppreMol GmbH, H2 2012
- Viromed Co., Ltd., H2 2012
- Ferring Pharmaceuticals, Inc., H2 2012
- Aphoenix, Inc., H2 2012
- Taisho Toyama Pharmaceutical Co., Ltd, H2 2012
- Domainex Ltd., H2 2012
- Cellceutix Pharmaceuticals, Inc., H2 2012
- Dynamix Pharmaceuticals Ltd., H2 2012
- Amplimmune, Inc., H2 2012
- Lycera Corp., H2 2012
- Perseid Therapeutics LLC, H2 2012
- OHR Pharmaceutical Inc., H2 2012
- ImmunoFrontier, Inc., H2 2012
- Femta Pharmaceuticals, Inc., H2 2012
- Cellmid Ltd, H2 2012
- Mebiopharm Co., Ltd., H2 2012
- ToleroTech Inc., H2 2012
- Diurnal Ltd, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Rheumatoid Arthritis Therapeutics – Drug Profile Updates
- Rheumatoid Arthritis Therapeutics – Discontinued Products
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..1)
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..2)
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..3)
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..4)
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..5)
- Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..6)
- Rheumatoid Arthritis Therapeutics – Dormant Products
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..1)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..2)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..3)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..4)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..5)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..6)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..7)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..8)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..9)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..10)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..11)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..12)
- Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..13)
- List of Figures
- Number of Products under Development for Rheumatoid Arthritis, H2 2012
- Products under Development for Rheumatoid Arthritis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractRheumatoid Arthritis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H2 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Rheumatoid Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
